View all cases
UPC APP 11261/2025
EP2401365 · REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION
- Case details
- Status—ActionPreliminary objectionCategoryPreliminary objection
- Parties
- Respondents
- BioNTech SEOperating co.
- BioNTech Manufacturing GmbHOperating co.
- BioNTech Manufacturing Marburg GmbHOperating co.
- BioNTech Innovative Manufacturing Services GmbHOperating co.
- BioNTech Europe GmbHOperating co.
- Pfizer Manufacturing Belgium NVOperating co.
- Pfizer SASOperating co.
- Pfizer ABOperating co.
- Pfizer Inc.Operating co.
Representatives- Christine Kanz-Hoyng Rokh Monegier
- Tobias J. Hessel-Clifford Chance Partnerschaft mbB
- Division
- Munich LD
- Judges
- Technology
- ChemistryBiotechnology
- Language
- —
- First decided
- Apr 17, 2025
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Munich LD | Locked |
| Judge András Kupecz | Locked |
At the UPC: Promosome LLC (15 cases)·BioNTech Group (21 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 14 other proceedings
UPC CoA 146/2026·UPC CoA 147/2026·UPC CoA 148/2026·UPC CFI 2819/2026·UPC CFI 2821/2026 and 9 more
Decisions
- 2025-04-17Preliminary objectionPublic
Summary: The Local Division Munich ruled on preliminary objections filed by BioNTech and Pfizer entities challenging UPC jurisdiction over Comirnaty COVID-19 vaccine variants sold before 1 June 2023, addressing the UPC's temporal jurisdiction in relation to the opt-out regime and the date of UPC operation.
Show the legal issues (4)
- Preliminary objection – jurisdiction (R.19 RoP)
- Temporal jurisdiction of UPC
- Opt-out regime
- COVID-19 vaccine infringement claim
Documents
- 461EA1D1D0D9579BEC10A6A7C20AE019_en.pdf2025-04-17EN